ReviewExperimental hematology & oncology2026
Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications.
Review in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Methionine is essential for protein synthesis and serves as a precursor to S-adenosylmethionine, supporting epigenetic modifications and cell growth. Unlike normal cells, cancer cells are dependent on methionine. Therapeutic strategies targeting metabolic vulnerability show promise but face challenges related to tumor heterogeneity and adaptive resistance, limiting clinical translation. This review comprehensively explores methionine metabolism in cancer, detailing its uptake, transport, and metabolic pathways that underpin tumor development. We examine tumor dependency on methionine across various cancer types and subtypes, highlighting oncogene-driven variability, including the pivotal roles of methionine adenosyltransferases (MATs), the methionine salvage enzyme 5'-methylthioadenosine phosphorylase (MTAP), and polyamine synthesis enzymes such as ornithine decarboxylase (ODC) and adenosylmethionine decarboxylase 1 (AMD1). Epigenetic contributions involving DNA, RNA, and histone methylation are discussed, emphasizing their tissue-specific implications, such as the MATI/III:MATII ratio in liver cancer and methionine metabolic features in glioblastoma, including PET imaging applications. This review further addresses methionine metabolic plasticity within the tumor microenvironment, focusing on epigenetic and immune reprogramming, metabolic checkpoint regulation, and the role of methionine in tumor-initiating cells and cancer stem cells. Therapeutic strategies targeting methionine dependence, including dietary restriction, methioninase enzyme therapies, transporter inhibition, and combination regimens aimed at enhancing efficacy, are critically evaluated. Finally, we discuss current challenges and future directions, emphasizing the need for tumor-selective interventions, improved delivery systems, and personalized metabolic diagnostics to translate metabolic vulnerabilities into effective clinical cancer therapies. This integrated analysis underscores the potential of targeting methionine metabolism for advancing cancer treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.